Yuceer Ramazan Oguz, Aydin Sedanur, Ozer Hatice, Aydin Asim Armagan, Yilmaz Mukaddes, Kaya Seyhmus, Koc Tulay
Department of Pathology, Cumhuriyet University School of Medicine, Sivas, Turkey.
Department of Clinical Oncology, Antalya Education and Research Hospital, Health Sciences University, Antalya, Turkey.
Medicine (Baltimore). 2025 Jun 27;104(26):e43110. doi: 10.1097/MD.0000000000043110.
This study aimed to evaluate the prognostic and predictive significance of Claudin-6 and trophoblast cell surface antigen-2 (Trop-2) expression in serous ovarian carcinoma, assessing their influence on treatment efficacy and clinical outcomes. A retrospective cohort of 73 patients diagnosed with serous ovarian carcinoma was analyzed. All patients underwent standard cytoreductive surgery, with or without neoadjuvant or adjuvant chemotherapy. Immunohistochemistry was used to assess the expression levels of Claudin-6 and Trop-2. Survival outcomes were evaluated using Kaplan-Meier and Cox proportional hazards models, with overall survival (OS) as the primary endpoint. High Trop-2 expression was observed in 67.1% of the patients, while 46.6% exhibited high Claudin-6 expression. Both markers were more common in older, postmenopausal patients, those with larger tumors, and those with distant metastasis. However, no significant associations were found with clinical factors (P > .05). Survival analysis demonstrated that high Trop-2 and Claudin-6 expression were associated with shorter OS and progression-free survival (PFS). Patients with high Trop-2 expression exhibited a median OS of 38 months and PFS of 32 months, whereas those with low Trop-2 expression had a median OS of 62 months and PFS of 60 months (OS: P = .039, PFS: P = .020). Similarly, high Claudin-6 expression was associated with a median OS of 32 months and PFS of 21 months, compared to an OS of 60 months and PFS of 56 months in patients with low Claudin-6 expression (OS: P = .005, PFS: P = .003). Both univariate and multivariate analyses confirmed that advanced age, and high Trop-2, and high Claudin-6 expression were significant predictors of poor OS and PFS (P < .05). These findings underscore the prognostic significance of Claudin-6 and Trop-2 in ovarian cancer, with elevated expression correlating with poorer survival outcomes. These markers may serve as independent prognostic factors, and their targeting through antibody-drug conjugates offers a potential therapeutic strategy to improve survival outcomes and overcome treatment resistance.
本研究旨在评估Claudin-6和滋养层细胞表面抗原2（Trop-2）表达在浆液性卵巢癌中的预后和预测意义，评估它们对治疗效果和临床结局的影响。分析了73例诊断为浆液性卵巢癌患者的回顾性队列。所有患者均接受了标准的肿瘤细胞减灭术，无论是否接受新辅助或辅助化疗。采用免疫组织化学法评估Claudin-6和Trop-2的表达水平。以总生存期（OS）为主要终点，使用Kaplan-Meier法和Cox比例风险模型评估生存结局。67.1%的患者观察到高Trop-2表达，而46.6%的患者表现为高Claudin-6表达。这两种标志物在年龄较大、绝经后患者、肿瘤较大以及有远处转移的患者中更为常见。然而，未发现与临床因素有显著关联（P>0.05）。生存分析表明，高Trop-2和Claudin-6表达与较短的OS和无进展生存期（PFS）相关。高Trop-2表达的患者中位OS为38个月，PFS为32个月，而低Trop-2表达的患者中位OS为62个月，PFS为60个月（OS：P=0.039，PFS：P=0.020）。同样，高Claudin-6表达与中位OS为32个月和PFS为21个月相关，而低Claudin-6表达的患者OS为60个月，PFS为56个月（OS：P=0.005，PFS：P=0.003）。单因素和多因素分析均证实，高龄、高Trop-2和高Claudin-6表达是OS和PFS不良的显著预测因素（P<0.05）。这些发现强调了Claudin-6和Trop-2在卵巢癌中的预后意义，表达升高与较差的生存结局相关。这些标志物可能作为独立的预后因素，通过抗体-药物偶联物靶向它们提供了一种潜在的治疗策略，以改善生存结局并克服治疗耐药性。
Cochrane Database Syst Rev. 2022-9-26
Cochrane Database Syst Rev. 2011-8-10
Cochrane Database Syst Rev. 2022-8-30
Cochrane Database Syst Rev. 2022-7-12
Cochrane Database Syst Rev. 2018-2-6
Cochrane Database Syst Rev. 2022-2-16
CA Cancer J Clin. 2025
Drug Des Devel Ther. 2024
Cancers (Basel). 2024-7-15
Am J Physiol Cell Physiol. 2024-8-1
Gynecol Oncol. 2024-8
Nat Rev Clin Oncol. 2024-5
Mol Cancer. 2024-3-28
Zotero 插件
